Oppenheimer analyst Matt Biegler downgraded Relay Therapeutics (NASDAQ: RLAY) from Outperform to Perform.
The analyst comments: "On Monday (9/9/24), Relay ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE